Follow-Ons Off? FDA Shelves Near-Term Plans For Biologics Documents
Executive Summary
FDA's decision not to release follow-on biologics documents in the near future suggests proponents of such products may turn their focus to Congress or the courts in an effort to establish a clear regulatory framework
You may also be interested in...
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA's Critical Path opportunities list suggests that the agency is actively working to lay the scientific groundwork for follow-on biologics
Tale Of Two Pathways: Follow-On Biologics Move Forth In EU, Stall In U.S.
The European Medicines Agency's endorsement of Sandoz' human growth hormone Omnitrope could put further pressure on U.S. regulators to develop an approval pathway for follow-on biologics